Menu ×


Irritable Bowel Syndrome Drugs Market Segmentation by Type {IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M)}; by Product (Eluxadoline, Lubiprostone, Rifaximin, Linaclotide, and Others); by End User (Drug Stores & Retail, Hospital, and Online Pharmacies); by Product (Xifaxan, Linzess, Amitiza, Viberzi, and Others) – Global Demand Analysis & Opportunity Outlook 2029

  • Text Size:

Extensive insights into the Growth of Irritable Bowel Syndrome Drugs Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

Irritable Bowel Syndrome Drugs Market Highlights 2020 – 2029

The irritable bowel syndrome (IBS) drugs market is anticipated to garner a large revenue by growing at a significant CAGR over the forecast period i.e. 2021 – 2029. The key factors that are estimated to drive the growth of the market are rise in the geriatric population, increasing prevalence of gastrointestinal diseases, escalating intake of unhealthy foods worldwide and growing stress levels among population globally. It was calculated that about 11% - 14% people in the United States of America suffer from irritable bowel syndrome. In addition to these, hike in availability of over-the-counter medications and surging investments by key players to develop effective cure for IBS are other factors considered to drive market growth. Moreover, rising number of awareness campaigns regarding the treatment of irritable bowel syndrome is expected to offer opportunities for the expansion of market in the near future.

The market is segmented by type into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS (IBS-M), out of which, the IBS with diarrhea (IBS-D) segment is anticipated to hold leading share in the irritable bowel syndrome drugs market. This can be accounted to the growing prevalence of constipation and diarrhea and increase in consumption of medicines such as linaclotide and lubiprostone. Furthermore, based on product, the segment for Xifaxan is estimated to gather the largest market share during the forecast period owing to the escalating adoption of the drug and its success to stop the growth of harmful bacteria. However, the Linzess segment is expected to witness highest CAGR in the near future ascribing to the increasing usage of this drug in China, Japan and Europe.

Irritable Bowel Syndrome Drugs Market

Global Irritable Bowel Syndrome Drugs Market Regional Synopsis

The irritable bowel syndrome drugs market is segmented into five major regions, including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America is projected to lead the worldwide market in terms of share owing to the availability of cheap fast food and growing trend of sedentary lifestyle in the region. In addition to this, Europe region is expected to also hold a significant market share, which can be credited to the presence of the key players who are into manufacturing various medical treatments for IBS. Moreover, Asia-Pacific is predicted to offer attractive prospects for market growth during the forecast period owing to the growing awareness about irritable bowel syndrome and rising acceptance of products used for the treatment of IBS in the region. Expansion of healthcare infrastructure, increasing number of hospitals with specialized medical facilities and surge in innovation in healthcare technologies are also anticipated to drive the growth of the market in the region in the coming years. CLICK TO DOWNLOAD SAMPLE REPORT

Global Irritable Bowel Syndrome Drugs Market

The irritable bowel syndrome drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Growth Drivers

  • Rising Prevalence of Irritable Bowel Syndrome
  • Increasing Availability of Over the Counter Medicines


  • Absence of Specific Treatment for IBS Symptoms
  • Growing Competition among Key Players

Market Segmentation

Our in-depth analysis of the irritable bowel drugs market includes the following segments:

 By Type

  • IBS with Diarrhea (IBS-D)
  • IBS with Constipation (IBS-C)
  • Mixed IBS (IBS-M)

By Product

  • Xifaxan
  • Linzess
  • Amitiza
  • Viberzi
  • Others

By End User:

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Top Companies Dominating the Market

  • Abbott Services
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Ironwood Pharmaceuticals, Inc.
  • Synergy Pharma Consultancy Private Limited
  • Synthetic Biologics, Inc


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved